Navigation Links
Local Research Foundation Achieves Milestone in Fight Against Cancer
Date:10/23/2008

is expected to last 12-15 months.

The CHRISTUS Stehlin Foundation is hopeful about the results of these clinical trials, as CZ48 has been shown in pre-clinical studies to exhibit a broad spectrum of anticancer activity against a wide array of human cancers growing in nude mice with a striking lack of toxicity. CZ48 is also innovative in that it can be taken orally, and pre-clinical studies indicate that it has very few side effects. This makes its appeal even stronger for human cancer treatment.

"We have always felt that CZ48 holds tremendous promise as a cancer treatment, which is why we have worked so diligently to make it available," said Dr. Beppino Giovanella, laboratory director at the CHRISTUS Stehlin Foundation for Cancer Research. "It is our hope that CZ48 will continue the legacy of the foundation and bring renewed hope and life to people around the world who suffer from cancer."

About the CHRISTUS Stehlin Foundation for Cancer Research

The CHRISTUS Stehlin Foundation for Cancer Research has developed and supported many innovative and life-saving treatments for patients with cancer, including being some of the first to recommend a lumpectomy for women with breast cancer. The CHRISTUS Foundation also innovated the use of nude mice in cancer research. Nude mouse tests are now the final, non-human studies required by the National Cancer Institute for determining the effectiveness of potential anticancer agents. Many scientists around the world consider the nude mouse one of the 20th century's most significant breakthroughs in cancer research.

The foundation was established by Dr. John S. Stehlin Jr., a cancer specialist and surgeon, with a specific and urgent mission: to find and develop the most effective treatments for the patient who suffered from cancer in the shortest period of time. In reaction to his mounting frustration with the traditional approach to cancer treatment, he developed a tripartnership concept between
'/>"/>

SOURCE CHRISTUS Stehlin Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants
2. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
3. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
4. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
5. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
6. New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases
7. On World AIDS Day, CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV/AIDS
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... and NEW YORK , October 1, 2014 /PRNewswire/ ... (CRO) and service provider for the medical industries, announced today the ... in New York City . genae Americas was ... is strategically centered in one of the highest concentrations of ... Philippe Kassab , President at genae Americas. "The expansion of ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems (NYSE: ... report results for the fourth quarter of fiscal year ... October 22, 2014.  The news release will be followed ... 2:00 p.m. PT.  The news release and a link ... the company website at: www.varian.com/investor .  To access ...
(Date:10/1/2014)... , Oct. 1, 2014 Quantum ... scaling volume production of photoactive quantum dots for ... . While offering numerous advantages for solar power ... large quantities of quantum dots with which to ... kept them from commercial utilization and acceptance. The ...
Breaking Medicine Technology:genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... Medical School ,Contributing Editor , ,With over ... breast cancer undoubtedly qualifies as one of Americas ... develop early detection methods and more effective therapy ... true at the molecular level, where discoveries on ...
... located on the short arm of chromosome 6 (6p21.3), is ... HLA region is the human equivalent of the Major Histocompatibility ... that serve as the backbone of antigen presentation. The ... CD8+ T-cells, are expressed by genes located in the HLA-A, ...
Cached Medicine Technology:Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 2Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 3The Past, Present and Future of HLA Typing 2The Past, Present and Future of HLA Typing 3
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... the business worldwide. This rapid growth includes increased hiring ... manufacturing efforts. The company has experienced average annual growth ... expects this growth to continue in the future as ... adoption. , “We are very pleased that ...
(Date:10/1/2014)... 2014 Farmington Company today announced ... mission and visual identity helping brokers, consultants and ... them to create greater benefit communication synergies. They ... on empowering customers to better leverage Farmington Company’s ... jewel of the rebrand is the refreshed tagline: ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... Kennebunkport, Maine (PRWEB) October 01, 2014 ... autoimmune disorders in the U.S., according to figures from ... Autoimmune Related Diseases Association (AARDA), and many of them ... higher chance of having undiagnosed celiac disease. Gluten ... helping raise awareness of undiagnosed celiac disease by publishing ...
(Date:10/1/2014)... 2014 Diet Doc understands that many of ... weight and their dieting attempts could be easily sabotaged by ... hormone diet treatments into their programs as a way ... fast and effective weight loss results, it also allows patients ... to maintain their weight for the future. , Earlier versions ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... cancer patients who exhibit limited lymph node involvement may ... neoadjuvant chemotherapy before a mastectomy, according to researchers from ... , The findings were reported today at the ... Radiology and Oncology. , "Radiation after surgery has been ...
... can affect practice behavior in inquiries about patient mood ... study led by University of Rochester Medical Center researchers. ... or attitudes, are loathe to broach sensitive topics such ... professor of psychiatry at the Medical Center and lead ...
... 24 As Senators Barack,Obama and John McCain arrive ... be greeted by AIDS activists from across the,country demanding ... his first 100 days in office., On Friday, ... the debate -,AIDS activists will hold a demonstration and ...
... Cooper University,Hospital in Camden, N.J., has agreed ... interest, to settle allegations that it defrauded ... settlement resolves allegations that the hospital improperly,increased ... reimbursement,from the federal health care program. In ...
... training in 60s, 70s wards off loss that weakens ... -- Strength training can help people build muscle mass to ... age until they reach 80, a new study says. , ... , The Ball State University study, sponsored by a ...
... The U.S. Pharmacopeial (USP) Convention is pleased to ... Material (CRM), Dextromethorphan Hydrobromide. USP recently became the ... Standardization accreditation as producer of chemical CRMs. ... new class of reference standard that ensures improved ...
Cached Medicine News:Health News:Cancer patients who receive neoadjuvant therapy followed by mastectomy may not need radiation 2Health News:Personality can hamper a physician's assessment of depression 2Health News:AIDS Activists from Across the Country Converge on Oxford, Mississippi, to Call on McCain and Obama to Commit to National AIDS Strategy 2Health News:New Jersey Hospital to Pay $3.85 Million to Resolve Allegations of Inflating Charges to Obtain Higher Medicare Reimbursement 2Health News:Boomers Should Add Muscle Before It's Too Late 2
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
... Fast-Cath, Maximum, Maximum Xtra, and ... line of standard and specialty hemostasis ... recognized as the premier hemostasis introducers ... electrophysiology procedures including angiography, angioplasty, stenting, ...
... to close arteriotomies with ease and ... a simple trigger actvated mechanism, requires ... sheath gently locks onto the target ... site before, during, and after the ...
The Prostar XL 10 is a suture mediated closure system. It can be used with 10F sheath. It has two 3-0 braided polyester sutures and also has the safety of guidewire....
Medicine Products: